AstraZeneca Divests Entocort GI Drug

AstraZeneca will sell the rights to its gastrointestinal drug Entocort outside the U.S. to Tillotts Pharma.

Switzerland-based Tillotts will pay $215 million in a transation that is expected to complete in the second half of 2015.

AstraZeneca continues to spin off non-core businesses in order to focus on selected therapy areas, such as oncology and diabetes.

Read the Reuters release

[javascriptSnippet ]